Boehringer Ingelheim Opens R&D Center In Shanghai; Sees Sales Growth From Products On NDRL Reimbursement List

SHANGHAI - Boehringer Ingelheim, the largest family-controlled pharma company, recently announced the opening of its Center of Competence in Shanghai. During the past year, the company invested €10 million to build the R&D center, which specializes in optimizing active pharmaceutical ingredients and chemical intermediates procured in China